Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression

Cardiovascular Research

Volumn 92, Issue 2, 2011, Pages 296-306

  Xie, Hui ^a   Xie, Ping Li ^b   Wu, Xian Ping ^a   Chen, San Mei ^b   Zhou, Hou De ^a   Yuan, Ling Qing ^a   Sheng, Zhi Feng ^a   Tang, Si Yuan ^b   Luo, Xiang Hang ^a   Liao, Er Yuan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Arterial calcification; Bone; Omentin 1; Osteoprotegerin; Receptor activator for nuclear factor B ligand

Indexed keywords

ADENOVIRUS VECTOR; ADIPOCYTOKINE; OMENTIN 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTERY CALCIFICATION; ARTICLE; BONE DENSITY; BONE METABOLISM; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ACID PHOSPHATASE; ADIPONECTIN; ANIMALS; BONE DENSITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GENE THERAPY; GPI-LINKED PROTEINS; HUMANS; ISOENZYMES; LECTINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOBLASTS; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR CALCIFICATION;

EID: 80054123717     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr200     Document Type: Article

References (51)

1. Persy V, D'Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 2009;15:405-416.
2. D'Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest 2009;32:6-9.
3. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268. (Pubitemid 28213402)
4. Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, Koriyama H et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 2010;107:466-475.
5. Poulos SP, Hausman DB, Hausman GJ. The development and endocrine functions of adipose tissue. Mol Cell Endocrinol 2010;323:20-34.
6. Allende-Vigo MZ. Pathophysiologic mechanisms linking adipose tissue and cardiometabolic risk. Endocr Pract 2010;16:692-698.
7. Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005;1732:96-102. (Pubitemid 43267310)
8. Yang RZ, Lee MJ, Hu H, Pray J,Wu HB, Hansen BC et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E1253-E1261. (Pubitemid 43847911)
9. Komiya T, Tanigawa Y, Hirohashi S. Cloning of the novel gene intelectin, which is expressed in intestinal Paneth cells in mice. Biochem Biophys Res Commun 1998;251: 759-762. (Pubitemid 28512784)
10. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56: 1655-1661. (Pubitemid 46842600)
11. Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010;7:27.
12. Tan BK, Pua S, Syed F, Lewandowski KC, O'Hare JP, Randeva HS. Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabet Med 2008;25:1254-1255.
13. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010;88:29-33.
14. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010; 393:668-672.
15. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011;408:339-343.
16. Duan XY, Xie PL, Ma YL, Tang SY. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids 2010; doi: 10.1007/s00726-010-0800-3. Published online ahead of print 17 November 2010.
17. Li H, Xie H, LiuW, Hu R, Huang B, Tan YF et al. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 2009;119:3666-3677.
18. Xie H, Sun M, Liao XB, Yuan LQ, Sheng ZF, Meng JC et al. Estrogen receptor a36 mediates a bone-sparing effect of 17b-estrodiol in postmenopausal women. J Bone Miner Res 2011;26:156-168.
19. Yuan LQ, Liu W, Cui RR, Wang D, Meng JC, Xie H et al. Taurine inhibits osteoclastogenesis through the taurine transporter. Amino Acids 2010;39:89-99.
20. Luo XH, Zhao LL, Yuan LQ, Wang M, Xie H, Liao EY. Development of arterial calcification in adiponectin-deficient mice: adiponectin regulates arterial calcification. J Bone Miner Res 2009;24:1461-1468.
21. Liao XB, Peng YQ, Zhou XM, Yang B, Zheng Z, Liu LM et al. Taurine restores Axl/Gas6 expression in vascular smooth muscle cell calcification model. Amino Acids 2010;39:375-383.
22. Xie H, Tang SY, Cui RR, Huang J, Ren XH, Yuan LQ et al. Apelin and its receptor are expressed in human osteoblasts. Regul Pept 2006;134:118-125.
23. Liu J, Xu K, Wen G, Guo H, Li S, Wu X et al. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. Bone 2008;42:950-959.
24. Sheng ZF, Xu K, Ma YL, Liu JH, Dai RC, Zhang YH et al. Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice. Osteoporos Int 2009;20:151-159.
25. Díez JJ, Iglesias P. The role of the novel adipocyte-derived protein adiponectin in human disease: an update. Mini Rev Med Chem 2010;10:856-869.
26. Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des 2010;16:1896-1901.
27. Chiarugi P, Fiaschi T. Adiponectin in health and diseases: from metabolic syndrome to tissue regeneration. Expert Opin Ther Targets 2010;14:193-206.
28. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309:99-109. (Pubitemid 41191227)
29. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts via the MAPK signaling pathway. J Bone Miner Res 2006;21:1648-1656. (Pubitemid 44484610)
30. Zhang H, Xie H, Zhao Q, Liao EY, Xie GQ, Wu XP et al. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in postmenopausal Chinese women. J Endocrinol Invest 2010;33:707-711.
31. Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 2008;387:31-35. (Pubitemid 350050925)
32. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93: 165-176. (Pubitemid 28180851)
33. Hsu HL, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545. (Pubitemid 29168945)
34. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009;104:1041-1048.
35. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319. (Pubitemid 27199902)
36. Lloyd SA, Yuan YY, Kostenuik PJ, Ominsky MS, Lau AG, Morony S et al. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcif Tissue Int 2008;82:361-372.
37. Yuan YY, Kostenuik PJ, Ominsky MS, Morony S, Adamu S, Simionescu DT et al. Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporos Int 2008;19:625-635.
38. Helas S, Goettsch C, Schoppet M, Zeitz U, Hempel U, Morawietz H et al. Inhibition of receptor activator of NF-kB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009;175:473-478.
39. Quercioli A, Luciano Viviani G, Dallegri F, Mach F, Montecucco F. Receptor activator of nuclear factor kappa B ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification. Crit Pathw Cardiol 2010;9: 227-230.
40. Nguyen KQ, Olesen P, Ledet T, Rasmussen LM. Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells. Endocrine 2007;32:52-58. (Pubitemid 350242547)
41. Watson KE, Boström K, Ravindranath R, Lam T, Norton B, Demer LL. TGF-b1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 1994;93:2106-2113.
42. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002;521:180-184. (Pubitemid 34628481)
43. Collett GD, Sage AP, Kirton JP, Alexander MY, Gilmore AP, Canfield AE. Axl/phosphatidylinositol 3-kinase signaling inhibits mineral deposition by vascular smooth muscle cells. Circ Res 2007;100:502-509. (Pubitemid 46673259)
44. Ulici V, Hoenselaar KD, Agoston H, McErlain DD, Umoh J, Chakrabarti S et al. The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification. Bone 2009;45:1133-1145.
45. Yan MZ, Xu Y, Gong YX, Liu JM, Lu SY, Huang L et al. Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism. Endocrine 2010;37:55-61.
46. Zillikens MC, Uitterlinden AG, van Leeuwen JP, Berends AL, Henneman P, van Dijk KW et al. The role of body mass index, insulin, and adiponectin in the relation between fat distribution and bone mineral density. Calcif Tissue Int 2010;86: 116-125.
47. Morin S, Tsang JF, Leslie WD. Weight and body mass index predict bone mineral density and fractures in women aged 40 to 59 years. Osteoporos Int 2009;20:363-370.
48. Morin S, Leslie WD, Manitoba Bone Density Program. High bone mineral density is associated with high body mass index. Osteoporos Int 2009;20:1267-1271.
49. Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 2007;92:1640-1646. (Pubitemid 46997165)
50. Lee CD, Jacobs DR Jr, Schreiner PJ, Iribarren C, Hankinson A. Abdominal obesity and coronary artery calcification in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Clin Nutr 2007;86:48-54. (Pubitemid 47041592)
51. Golledge J, Jayalath R, Oliver L, Parr A, Schurgers L, Clancy P. Relationship between CT anthropometric measurements, adipokines and abdominal aortic calcification. Atherosclerosis 2008;197:428-434. (Pubitemid 351273264)